EAS 2019 Prof. Chapman lists the newest findings on the associations of Lp(a) levels, PCSK9 inhibitors and CV risk, based on new analyses of the FOURIER and ODYSSEY OUTCOMES trials.
This video was recorded at the EAS in Maastricht, the Netherlands, on May 29, 2019.
John Chapman is Research Professor at the Sorbonne University, is affiliated with the Endocrinology-Metabolism Division of the Pitié-Salpêtrière University Hospital, and is Director Emeritus of the National Institute for Health and Medical Research (INSERM) in Paris, France.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Professor Kausik Ray, MD
Prof. Evan Stein